Coccidioidomycosis - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Coccidioidomycosis - Pipeline Review, H1 2019’, provides an overview of the Coccidioidomycosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Coccidioidomycosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coccidioidomycosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Coccidioidomycosis

- The report reviews pipeline therapeutics for Coccidioidomycosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Coccidioidomycosis therapeutics and enlists all their major and minor projects

- The report assesses Coccidioidomycosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Coccidioidomycosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Coccidioidomycosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Coccidioidomycosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amplyx Pharmaceuticals Inc

F2G Ltd

Valley Fever Solutions Inc

Viamet Pharmaceuticals Inc

Amplyx Pharmaceuticals Inc

F2G Ltd

Valley Fever Solutions Inc

Viamet Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Coccidioidomycosis – Overview

Coccidioidomycosis – Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Coccidioidomycosis – Overview

Coccidioidomycosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Coccidioidomycosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Coccidioidomycosis – Companies Involved in Therapeutics Development

Amplyx Pharmaceuticals Inc

F2G Ltd

Valley Fever Solutions Inc

Viamet Pharmaceuticals Inc

Coccidioidomycosis – Drug Profiles

Amphotericin B sodium – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

coccidioidomycosis vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nikkomycin Z – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olorofim – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1161 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1598 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coccidioidomycosis – Dormant Projects

Coccidioidomycosis – Product Development Milestones

Featured News & Press Releases

Jun 07, 2018: Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host

Jul 13, 2017: FDA Grants Fast Track Designation to VT-1598 for Treatment of Valley Fever

May 17, 2017: Viamet To Present Data on VT-1598 at The American Society for Microbiology's ASM Microbe 2017 Conference

Nov 16, 2016: FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections

Sep 15, 2016: FDA Grants QIDP Designation to VT-1598 for Treatment of Valley Fever

Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections

May 25, 2016: Viamet Receives Orphan Drug Designation from the FDA for VT-1598 for the Treatment of Coccidioidomycosis

May 20, 2015: Viamet Announces NIH Grant for Compounds Directed at Valley Fever

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Coccidioidomycosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Tables

Number of Products under Development for Coccidioidomycosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Coccidioidomycosis – Pipeline by Amplyx Pharmaceuticals Inc, H1 2019

Coccidioidomycosis – Pipeline by F2G Ltd, H1 2019

Coccidioidomycosis – Pipeline by Valley Fever Solutions Inc, H1 2019

Coccidioidomycosis – Pipeline by Viamet Pharmaceuticals Inc, H1 2019

Coccidioidomycosis – Dormant Projects, H1 2019

List of Figures

List of Figures

Number of Products under Development for Coccidioidomycosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by ...

List of Figures

Number of Products under Development for Coccidioidomycosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports